MedTrace Logo

Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients

NCT03829852 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 716

Last updated 2021-07-23

No results posted yet for this study

Summary

Regorafenib is currently the standard of care for refractory mCRC patients. Pivotal studies of regorafenib have proven the efficacy and safety, with a 28-day cycle (21 days on, 7 days off) and 160 mg dose given once daily.

In the clinic, patients often have some complicated condition. This study aims to perform retrospective medical chart review of mCRC patients who received regorafenib treatment in two medical centers in Taiwan to examine treatment effectiveness in the routine clinical practice setting.

Conditions

Interventions

DRUG

Regorafenib

Treatment was performed based on physician's discretion

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • Koo Foundation Sun Yat-Sen Cancer Center

    collaborator OTHER

  • Taipei Veterans General Hospital, Taiwan

    lead OTHER_GOV

Principal Investigators

  • Hao-Wei Teng, MD, PhD · Taipei Veterans General Hospital, Taiwan

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-11
Primary Completion
2020-12-08
Completion
2020-12-08

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03829852 on ClinicalTrials.gov